NIOX VERO. NIOX VERO device call-to-action. Order NIOX VERO. Contact us today to order your FeNO by NIOX device and other consumables. Order Now. Services and Markets Act (Financial Promotion) Order (as that shares in Aerocrine can be sold at a price acceptable to. The total value of the Offer, based on ,, shares in Aerocrine, amounts to SEK 1,,,[1] The Offer Price corresponds to a.

Author: Vubei Nakazahn
Country: Bosnia & Herzegovina
Language: English (Spanish)
Genre: Science
Published (Last): 8 January 2008
Pages: 217
PDF File Size: 16.27 Mb
ePub File Size: 13.80 Mb
ISBN: 418-9-84924-611-2
Downloads: 48181
Price: Free* [*Free Regsitration Required]
Uploader: Bramuro

Trading in subscription rights is expected to take place from 14 January up to and including 26 January Investors can use it for identifying and analyzing ongoing or future events that will have a significant impact on performance of publicly traded stocks.

Aerocrine AB B (XSTO:AERO B) – Share price – Chart

Sales figure represents last 12 months as of March 31, This will allow the company to realize its growth plans and reach profitability, and thereby create additional shareholder value. While airway inflammation is known to be the major underlying characteristic of asthma, there are few methods of measuring it.

Circassia has not received any other non-public information that could reasonably be expected to affect the price of the Aerocrine share in connection with the review. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June No underwriting fee has been requested by or paid to the underwriters. This press release may not be published, distributed, transmitted or otherwise sent pricfs the United States of America including its territories and possessions, every State aand the United States and the District of ColumbiaAustralia, Canada, Japan or South Africa or any other state or jurisdiction in which such release, publication or distribution would be unlawful.

The total value of the Offer, based on , shares in Aerocrine, amounts to SEK 1,, The subscription period subscription through payment will run from 14 January up to and including 28 Januaryor such later date as decided by the Board of Directors.

Catalyst Potential is a tool for our analyst to flag specific catalysts that may drive the share price.

Lovisagruvan, Peab, Aerocrine |

A company that does not grow may be a good short-term investment, but is usually unwise in the long term. Our Leadership rating represents an assessment of the ability of the adn and executive team to lead the company in the best interests of the shareholders. The Information was submitted for publication on May 15, at Once a position is taken, the Bull Case will help to avoid premature selling.

Profitability Our Profitability rating represents an assessment of how effective a company has historically utilised its capital to generate profit. But we also try to use specific information about the case to adjust the baseline prediction, if there are particular reasons to expect the optimistic bias to be more or less pronounced in this project than in others of the same type.


Patient enough to hold good investments at least until the market is willing to recognise its full potential. The change of control provisions would be triggered if a party would acquire shares representing more than 40 per cent of the votes of Aerocrine.

This press release may aerorine be released, published or distributed, nad or indirectly, in or into Australia, Hong Kong, Japan, Canada, Singapore, South Africa, the United States or any other jurisdiction where such action is wholly or partially subject to snd restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law.

The total number of points for these key sub-categories makes up ordeg rating for each category respectively, based on a scale that ranges from 0 to To date, over 18 million tests have been performed using a NIOX device, supporting clinicians to enhance the accuracy of diagnosis and better-personalized control.

An official ATS clinical practice guideline: This means that in case Circassia completes the Offer, even if such completion is made at a lower acceptance level than more than 90 per cent of the shares, the payment under the credit agreement may be accelerated pricws the prepayment penalty may become due and payable. Our Profitability rating represents an assessment of how effective a company has historically utilised its capital to generate profit. Identify important events short and longer term in duration that could be catalysts to cause the stock to perform significantly different than its peers or the broader market, i.

You are now entering a section of NIOX. The Board assumes that this description is accurate and has in relevant aspects no reason to take a different view.

CET on November 28, The Opinion is attached to this oeder. Circassia Ltd March These quantitative scores are grouped into five categories, each assessed on a number of quantitative and qualitative questions structured into different sub-categories. Circassia is offering SEK 2. Do you want to continue? This growth is expected to be achieved while the company is continuing to focus on overall expense control and selectively pursue growth opportunities with targeted funding.

In addition, the company will leverage the VERO product and software platform to finalize development of a home-treatment monitoring device in accordance with the recently published guidelines for home medical ofder by the FDA. Based on the above, the Board unanimously recommends the Aerocrine shareholders to accept the Offer. The Extraordinary General Meeting is planned to be held on 7 January The Board has, at the written request of Circassia, permitted Circassia to carry out a confirmatory due diligence review of Aerocrine in connection with the preparation of the Offer.


Aerocrine is based in Sweden with subsidiaries in the U.

Based on the proposed rights issue, and assuming it will be fully subscribed, liquidity is expected to be sufficient to continue the planned operations and attain positive cash flow without additional financing. This press release does not constitute an extension into the United States or any other jurisdiction of the Offer mentioned in this press release.

Important information The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Aerocrine. The Offer represents a multiple of 8. Accurately assess and monitor airway inflammation While airway inflammation is known to be the major underlying characteristic of asthma, there are few methods of measuring it. However, based on current forecasts, and absent a strategic collaboration or larger than expected growth in revenue, existing cash is sufficient to finance the current scope of operations until approximately the end of the second quarter ; and sufficient cash to meet the conditions of the credit agreement at least until the end of December Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma.

Since the end ofAerocrine has been undergoing a transition resulting in an increased corporate focus on sales and marketing execution, and the company has invested intensively in preparing and growing its US market presence.

This statement has been made in a Swedish and English version. Forward-looking statements inherently involve both known and unknown risks and snd as they depend on future events and circumstances.

Yet price and value are two very distinct concepts. Aerocrine shares were listed on the Stockholm Stock Exchange in Additional shares in Aerocrine may be issued following this point in time as a result of exercise of outstanding personnel stock options and warrants in Aerocrine, and any such additional shares shall be included in the Offer. Evaluating airway inflammation using induced sputum or airway biopsy is considered the gold standard however it is expensive, invasive, time-consuming, and often not readily available.